Gilead Sciences Management Discusses Q3 2012 Results - Earnings Call ... Seeking Alpha A third study evaluating 1101 with ofatumumab and CLL and two Phase III studies evaluating 1101 in combination with rituximab and with rituximab and bendamustine and iNHL will initiate later this year. In summary, the last few months of the year ... |
